Gastrointestinal

The Pharmacy Times® Gastrointestinal resource center provides news and articles centered around the FDA approved drugs in gastroenterology, as well as links to condition-specific resources, and videos and other content.

What can we help you find?

Risankizumab Demonstrates Significant Improvements In Patients with Crohn Disease

A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.

Only Gastrointestinal Symptoms Present in Nearly 20% of COVID-19 Cases

Despite presenting in only 18% of cases, 16% of all COVID-19 patients only present with gastrointestinal symptoms.

New Dupilumab Study Shows Improvement in Eosinophilic Esophagitis Signs, Symptoms

The FDA granted breakthrough therapy designation to dupilumab in September 2020, for the treatment of patients age 12 years and older with eosinophilic esophagitis.

Help Prevent and Treat Mild to Moderate GERD

Educate patients about the appropriate and safe use of gastrointestinal products and direct them to seek further medical care when warranted.

Dietary Fructose Worsens Inflammatory Bowel Disease

Like diabetes, Inflammatory bowel disease may also be linked to a high-fructose diet.

Plethora of Clinical Trials Explore Gastric Cancer Treatments

Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.

Amneal Resumes Shipping of Axid® Equivalent Nizatidine Oral Solution

Nizatidine Oral Solution is a prescription oral product used for the short-term treatment and maintenance therapy of ulcers and for the treatment of esophagitis and associated heartburn due to GERD.

Study: Antibiotic Use Increases Risk of Inflammatory Bowel Disease

Irritable bowel disease, such as ulcerative colitis and Crohn disease, can increase the risk of both cancer and death.

Antibiotic Use in Infants May Increase Risk of Inflammatory Bowel Disease Later in Life

According to a study published in Genome Medicine, the disruption of gut bacteria through the use of antibiotics soon after birth has the ability to affect the immune system’s process of maturation.

GERD Has a Variety of OTC Treatment Options

A variety of OTC products, such as antacids, histamine H2 receptor antagonists (H2RAs), and proton pump inhibitors (PPIs), are available to help manage symptoms of gastroesophageal reflux disease (GERD).

FDA Approves Biosimilar to Humira

Mylan plans to launch adalimumab-fkjp in the United States in July 2023.

Survey Finds Association Between Proton Pump Inhibitors, Risk of COVID-19

According to an online survey of more than 53,000 Americans using PPIs, once or twice daily use significantly increases the likelihood of a positive test for COVID-19.

The Pharmacy Times® Gastrointestinal resource center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of novel GI therapies, and the newest data from all phases of clinical trials and studies in the space. It also serves as a hub of information and news from the upcoming and ongoing conferences and annual meetings of gastrointestinal associations and societies, including pivotal coverage right from the floor.

Among its other resources are a wealth of videos including interviews with thought leaders and experts in GI, and moderated Peer Exchange panel discussions about the best practices and key methods for treating complex cases of conditions such as: constipation, irritable bowel syndrome, hemorrhoids, anal fissures, perianal abscesses, anal fistulas, perianal infections, diverticular diseases, colitis, colon polyps and cancer.